Yellen resolved to avoid raising rates too soon, fearing downturn
WASHINGTON/NEW YORK (Reuters) - Approaching a historic turn in U.S. monetary policy, Janet Yellen has staked her tenure as chair of the Federal Reserve on a simple principle: she'd rather fight inflation than another economic downturn.
Interviews with current and former Fed officials indicate that Yellen and core decision-makers at the U.S. central bank are determined not to raise interest rates too early and risk hurting the fragile U.S. economy.
It's a commitment that will be vigorously tested in coming months as pressure builds inside the Fed, among Republicans on Capitol Hill, and perhaps even in financial markets, for the Fed to acknowledge a strengthening U.S. economy with its first interest-rate increase in more than eight years. A global central bankers' conference in Jackson Hole, Wyoming next week will give Yellen a major stage on which to press her case.
After taking over from Ben Bernanke in February, she has developed a distinct style: off-the-cuff and personable in public appearances, unusually direct in calling attention to the plight of the unemployed, meticulous in her preparation for Fed meetings and highly attuned to the opinions of her colleagues, the Fed sources say.
A common adjective used to describe her in meetings is "over-prepared." She is able to deeply question staff and colleagues about the fine points of their presentations, and so far has been able to forge consensus statements that have satisfied the Fed hawks most concerned about the inflation threat while keeping the central bank focused more on employment.
The nightmare scenario she wants to avoid is hiking rates only to see financial markets and the economy take such a hit that she has to backtrack. Until the Fed has gotten rates up from the current level near zero to more normal levels, it would have little room to respond if the economy threatened to head into another recession.
Inflation, on the other hand, is a familiar foe that Fed officials say they are confident they can control with conventional policy tools.
"If the Fed were to generate too much economic growth and higher inflation, that is a much better situation to be in than one of a faltering economic recovery and the need to rely even more on unconventional tools," said David Stockton, the Fed's chief economist until 2011 who is now a senior fellow at the Peterson Institute for International Economics.
"The Fed knows how to contain inflation if it is moving," he said, while the impact at this point of another downturn "are more uncertain and hard to counter."
The risks of moving too soon, Stockton and others in and outside the Fed say, include snuffing out an already tepid housing market recovery with higher mortgage rates, depressing business investment and durable goods purchases, and triggering sudden declines in asset prices.
And after extraordinary efforts to right the U.S. economy after the financial crisis struck, there would likely be little appetite among Republicans or other fiscal conservatives on Capitol Hill to use fiscal policy to counter a fresh recession, making it all the more important for Yellen to avoid helping to cause such a reversal.
"The challenge that she and the Fed as an institution face is to support the recovery, because fiscal policy ... is no longer on the table for both political and economic reasons," said David Lipton, first deputy managing director at the International Monetary Fund. "Now that (the economy) is recovering, the challenge is to gauge its strength and make sure it stays on the right path."
The other scary scenario is that a bout of swifter-than-expected inflation could erode three decades of hard-earned confidence that prices will remain under control, which in turn could make it easier for higher inflation to take firm root. The Fed's more hawkish officials also worry that the longer rates remain ultra low the more likely it is that troublesome financial bubbles will form.
Philadelphia Federal Reserve Bank President Charles Plosser formally dissented over the current dovish approach at the central bank's last policy meeting, while in recent weeks Richard Fisher of the Dallas Fed has amplified his concern that the bank is falling behind the inflation curve.
But even Fisher, one of the Fed's most outspoken hawks, credited Yellen's "extremely thoughtful" way of taking into account the views of other policymakers, a factor he said prompted him not to dissent.
"She may be new to the chair but she's well respected and she knows all the personalities in the room," said former Fed Governor Elizabeth Duke. Jeffrey Fuhrer, senior policy advisor at the Boston Fed, said Yellen's communications style is "a little more open and accessible" than her predecessor Bernanke. Adding: "She's a bit more approachable somehow."
The central bank is also watching the November mid-term elections with particular interest: a Republican takeover of the Senate could give momentum to a proposal that would force the Fed to rely on a mechanistic rule to set interest rates based on the levels of inflation and unemployment in the economy. That would undermine the collective judgment Yellen feels is needed to guide the economy in the aftermath of the financial crisis.
Despite a falling unemployment rate and inflation that is rising toward the Fed's 2-percent target, Yellen has in the last six months managed to shift investors' attention to stagnant wage growth and the high number of Americans who have given up the search for work.
She recently described higher inflation readings as "noisy," noting that overshooting the target is "at most a risk that we could face somewhere down the road."
At an IMF event in early July, she dropped another strong clue that she was not afraid to let the economy heat up, saying the threat of asset-price bubbles or other financial instabilities probably won't prompt an earlier-than-expected policy tightening.
That speech has been cited by a number of analysts who know Yellen as an important sign that she is putting her stamp on the evolving debate over how deeply central banks should be concerned with financial stability. Yellen was clear: raising rates would almost certainly cost jobs and growth, but wouldn't necessarily stave off bubbles.
In yet another sign of the Fed's patience, San Francisco Fed chief John Williams, often cited as a policy bellwether, recently made the theoretical case for allowing inflation to run temporarily above target to help bring down the number of long-term unemployed. Even broaching the idea of letting inflation run hot is a sensitive topic for a central bank that in the late 1970s and early 80s hiked its key rates to as high as 20 percent to slay sky-rocketing price increases.
Investors currently do not expect the Fed to lift rates until the second half of next year - a remarkable achievement for Yellen given the U.S. unemployment rate is near a six-year low and closing in on what Fed officials see as its equilibrium level.
Colleagues said that Yellen has adapted easily to her new role, yet what Stockton called her "stress test" lies ahead, and may begin this fall when the debate over interest rates intensifies.
The Fed expects to end one of its key crisis programs in October when it stops buying Treasury bonds and mortgage backed securities. Once that happens, the next step is to raise rates.
"You're going to see a battle ... that is wide open" among policymakers, predicted former Fed Vice Chair Alan Blinder.
"There are a zillion ways it could go wrong but the simplest way is that the Fed exits too slowly, in which case some of the fears of the inflation hawks will come true," added Blinder, now a Princeton professor. "The other is that the Fed moves too quickly - this is the one that often gets forgotten - and the recovery stalls or, even worse, gets reversed."
Closing Market Summary: Stocks and Treasuries Register Modest Losses
The major averages stumbled on Tuesday with the Russell 2000 pacing the slide. The small-cap index lost 0.7%, while the S&P 500 (-0.2%) gave back most of its advance from yesterday. For its part, the Dow Jones Industrial Average (-0.1%) ended with a slim loss.
Equity indices spent the first hour of action near their flat lines after index futures slumped from their overnight highs shortly ahead of the cash open. The early weakness took place as markets in Europe retreated in reaction to disappointing survey data. Specifically, Eurozone ZEW Economic Sentiment plunged to 23.7 from 48.1 (expected 41.3), while Germany's ZEW Economic Sentiment dropped to 8.6 from 27.1 (consensus 18.2).
The news from overseas contributed to the shaky start and so did the underperformance of some closely-watched groups. Most notably, the top-weighted sector—technology (-0.2%)—spent the majority of the trading day in the red amid broad weakness. Chipmakers lagged early, but the PHLX Semiconductor Index was able to narrow its loss to 0.1% by the close. Meanwhile, most large cap tech components underperformed, while Apple (AAPL 95.97, -0.02), IBM (IBM 187.34, -0.13), and Microsoft (MSFT 43.52, +0.32) bucked the trend.
Similar to technology, the energy sector (-0.7%) also kept the market from staging a sustained rebound. The growth-sensitive sector finished near its session low, while crude oil fell 0.7% to $97.35/bbl.
Elsewhere, another influential sector—health care—was able to end just ahead of the broader market even as biotechnology weighed. The iShares Nasdaq Biotechnology ETF (IBB 251.66, -1.55) lost 0.6% and surrendered yesterday's gain.
Like health care, other countercyclical sectors finished near their flat lines. Consumer staples (-0.1%) and utilities (-0.1%) logged modest losses, while the weakest sector of the month—telecom services—added 0.5% to narrow its August decline to 2.5%.
Even though equities endured a sloppy session, participants did not rush in search of volatility protection. In fact, the CBOE Volatility Index (VIX 14.14, -0.09) finished in the red. The modest losses did not translate into higher demand for Treasuries either as the 10-yr note settled on its low with the benchmark yield up two basis points at 2.45%.
Participation was below average with 531 million shares changing hands at the NYSE floor.
Economic data was limited to the Job Opening and Labor Turnover Survey for June and the Treasury Budget for July:
* The Job Openings and Labor Turnover Survey for June indicated job opening increased to 4.671 million from 4.577 million * The Treasury Budget for July showed a deficit of $94.60 billion, which followed the prior deficit of $97.60 billion, while the Briefing.com consensus expected the deficit to hit $96.00 billion
Tomorrow, the weekly MBA Mortgage Index will be released at 7:00 ET, while the Retail Sales report for July (consensus 0.3%) will cross the wires at 8:30 ET. Separately, the Business Inventories report for June (consensus 0.4%) will be released at 10:00 ET.
* Nasdaq Composite +5.1% YTD * S&P 500 +4.6% YTD * Dow Jones Industrial Average -0.1% YTD * Russell 2000 -2.6% YTD
• AstraZeneca and GSK could look at InterMune
• Incyte, Pharmacyclics and BioMarin also watched
• Sanofi could eye BioMarin in 2016
European pharmaceutical firms looking to add to their portfolios could take advantage of a slew of US assets releasing late-stage clinical data and a calmer cross-border M&A market due to a possible clampdown on US tax inversion deals, bankers and analysts said.
UK-based AstraZeneca [LON:AZN] and GlaxoSmithKline [LON:GSK], which have spent the first half of the year reorganising their portfolios, could now look to the US in an effort to replenish and enhance existing pipelines, the bankers and analysts said.
Roche [VTX:ROG] and Sanofi [EPA:SAN], which are both on the hunt for acquisitions, could also be sounding out targets across the Atlantic to add advanced technologies and new orphan drug development science, one banker and analyst suggested.
US firms in the USD 5bn-USD 10bn size range would be affordable and provide European bidders with long-term revenues, two bankers and two analysts said. They named InterMune [NASDAQ:ITMN], BioMarin[NASDAQ:BMRN], Incyte Corporation [NASDAQ:INCY] and Pharmacyclics [NASDAQ:PCYC] as targets within this range.
Jazz Pharmaceuticals [NASDAQ:JAZZ] and Salix Pharmaceuticals [NASDAQ:SLXP], which are both UK-headquartered, also fall within this deal range, but European pharma would have to compete with US bidders willing to pay a tax inversion premium, one of the analysts said.
UK giants on the prowl
AstraZeneca and GSK, which have both undertaken strategies that have led them to focus on respiratory disorders, can better reap revenue if they have a presence across the gamut of respiratory indications, the analyst and banker said.
An acquisition of US-based InterMune, which has filed pirfenidone for idiopathic pulmonary fibrosis (IPF) for approval with the US FDA and is awaiting a response in 4Q14, would be a good fit for either AstraZeneca or GSK, they said.
GSK is developing a greater interest in the IPF space, a consulting physician said, while in May this year, AstraZeneca told this news service it was exploring more activity in IPF in its attempts to expand its respiratory portfolio.
GSK declined to comment. AstraZeneca did not return a request for comment.
There are not many firms specifically looking at IPF, so only players with an existing respiratory franchise would pay the price required to do a deal, the banker added. But, the asset would also interest players in inflammatory and orphan diseases, meaning that there would be many firms actively looking at InterMune, a second banker said.
Adding a premium, InterMune could fetch USD 5bn with a potential 10-15% upside if the US FDA approves the drug, pushing the price tag to up to USD 5.5bn - a deal that both GSK and AZ could comfortably afford, the analyst and banker said. With only one product in the late-stage pipeline, one would assume USD 1.5bn-USD 2bn peak sales are needed for InterMune to reach a value of USD 4bn-USD 5bn for a sale, an industry M&A lawyer said.
Bidders have so far refrained from moving in on InterMune, given the regulatory risk associated with pirfenidone's FDA approval quest. But, now that it has been approved in the EU and Canada, buyers are more willing to acquire, the third healthcare banker said.
US regulatory risks have been minimised with recent positive Phase III data presented at the American Thoracic Society (ATS) in May, physicians told this news service. The potential for pirfenidone to be studied in other fibrotic diseases in the lung or other organs are a long way from materialising, the consulting physician said. While GSK and AstraZeneca could find this potential an added bonus, such a possibility would not be compelling enough for non-respiratory focused pharma players, the analyst and banker agreed.
Furthermore, pirfenidone is unlikely to become a blockbuster that justifies its value with only one drug and preclinical candidates years away from success, an IPF physician said. Analyst forecasts of pirfenidone sales have varied from USD 600m to more than USD 1bn.
Intermune’s attraction would be to gain an established IPF sales force and revenue in Europe with the expectation of a US launch in 1H15, the physician said.
Competition from Boehringer Ingelheim’s IPF drug nintedanib, which saw positive Phase III results presented at ATS in May, could also dampen pirfenidone’s market uptake, according to a previousBiopharm Insight report. Boehringer’s existing powerful global respiratory sales force will be hard to compete with, the M&A lawyer added. As both drugs have similar mechanisms of action, uptake will be dependent on marketing execution, said a second consulting physician.
The attractive risk of new science
Roche - which recently snapped up Danish gene silencing company Santaris Pharma for USD 450m - and Sanofi - whose notable acquisition of Genzyme gave it a considerable presence in rare diseases, could both see BioMarin a potential target, one of the bankers and analysts said.
While BioMarin has “interesting science,” any predator would be buying into the company’s future potential, the analyst said. Additionally, Sanofi may be entertaining various options but might not have the appetite for any substantial M&A deals until 2016, the M&A lawyer said.
BioMarin's pipeline readouts are scheduled for June 2015. Its PARP inhibitor (BMN-673) for genetically defined cancers is likely to be an attractive proposition for Roche, the banker suggested. Roche has paid down its Genentech acquisition debt, which will allow it to finance its thirst for technology-driven acquisitions, he added.
Oncology products and companion diagnostics - as would be the case if Roche acquired Pharmacyclics to marry up the Gazyva (obinutuzumab) drug to its diagnostic - remains a core expertise and acquisitive interest for the Swiss giant, one of the bankers said.
Sanofi and Roche could not immediately be reached for comment.
BN 08/12 14:20 *RUSSIAN AID TO BE DELIVERED W/IN UKRAINE UNDER RED CROSS AEGIS
BN 08/12 14:18 *RUSSIA TO DELIVER AID TO BELGOROD-KHARKIV BORDER
BN 08/12 14:16 *RUSSIA COMPLYING W/ UKRAINE WISHES FOR CHECKING AID CARGOES
BFW 08/12 14:16 *RUSSIA IS FOLLOWING UKRAINIAN WISHES ABOUT AID CONVOY ROUTE
BN 08/12 14:16 *RUSSIA IS FOLLOWING UKRAINIAN WISHES ABOUT AID CONVOY ROUTE
2014-08-12 14:26:24.790 GMT
By Torrey Clark
Aug. 12 (Bloomberg) -- Russia to deliver aid to Belgorod-
Kharkiv border.
* NOTE: Earlier, Red Cross Seeking Information on Russian Aid
Convoy to Ukraine {NSN NA75W76TTDS3 <go>}
* NOTE: Earlier, Ukraine to Block Russian Aid Lacking Red
Cross’s Green Light {NSN NA74PV6JIJUS <go>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Torrey Clark in Moscow at +7-495-771-7709 or
tclark8@bloomberg.net
To contact the editor responsible for this story:
Joanna Ossinger at +1-212-617-7789 or
jossinger@bloomberg.net
2014-08-12 13:41:54.406 GMT
By Sam Chambers
Aug. 12 (Bloomberg) -- GBP15/month offer begins Aug. 14,
prior to start of Premier League season. Statement
* Aug 7: BT’s bid to offer Sky Sports in time for Premier
League season thwarted by by summer recess: Telegraph
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Sam Chambers in London at +44-20-7673-2021 or
schambers7@bloomberg.net
To contact the editor responsible for this story:
James Ludden at +44-20-7673-2645 or
jludden@bloomberg.net
BFW 08/12 13:00 *ECB SAYS GOLD, GOLD RECEIVABLES REMAINED UNCHANGED IN WEEK
2014-08-12 13:00:08.540 GMT
See {NSN NA72S6BE07IB <GO>} for the Government Web Content - Europe ex UK press release.
-0- Aug/12/2014 13:00 GMT
BN 08/12 12:50 *SANOFI LAUNCHES AUTHORIZED GENERIC VERSION OF ELOXATIN®
2014-08-12 12:55:31.626 GMT
By Allison Connolly
Aug. 12 (Bloomberg) -- Co. says its generics division
Winthrop U.S. has introduced a generic version of Eloxatin
(oxaliplatin injection).
* Sanofi holds original patent; generic is same formulation
* Used in treatment of advanced colorectal cancer or as
adjuvant treatment of stage III colon cancer in patients who
have undergone complete resection of the primary tumor
* NOTE: Branded drug lost market exclusivity in U.S. in Aug.
2012
Link to Statement:{NSN NA72C73MMTC0 <GO>}
Link to Company News:{SAN FP <Equity> CN <GO>}
For Related News and Information:
First Word scrolling panel: {FIRST<GO>}
First Word newswire: {NH BFW<GO>}
To contact the reporter on this story:
Allison Connolly in London at +44-20-3525-7043 or
aconnolly4@bloomberg.net
To contact the editor responsible for this story:
Allison Connolly at +44-20-3525-7043 or
aconnolly4@bloomberg.net